Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering med...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Caruso, Paola, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798345/
https://www.ncbi.nlm.nih.gov/pubmed/33430860
http://dx.doi.org/10.1186/s12933-021-01213-w
_version_ 1783635043938205696
author Giugliano, Dario
Longo, Miriam
Scappaticcio, Lorenzo
Caruso, Paola
Esposito, Katherine
author_facet Giugliano, Dario
Longo, Miriam
Scappaticcio, Lorenzo
Caruso, Paola
Esposito, Katherine
author_sort Giugliano, Dario
collection PubMed
description Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.
format Online
Article
Text
id pubmed-7798345
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77983452021-01-12 Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes Giugliano, Dario Longo, Miriam Scappaticcio, Lorenzo Caruso, Paola Esposito, Katherine Cardiovasc Diabetol Review Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i. BioMed Central 2021-01-11 /pmc/articles/PMC7798345/ /pubmed/33430860 http://dx.doi.org/10.1186/s12933-021-01213-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Giugliano, Dario
Longo, Miriam
Scappaticcio, Lorenzo
Caruso, Paola
Esposito, Katherine
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title_full Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title_fullStr Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title_full_unstemmed Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title_short Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
title_sort sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798345/
https://www.ncbi.nlm.nih.gov/pubmed/33430860
http://dx.doi.org/10.1186/s12933-021-01213-w
work_keys_str_mv AT giuglianodario sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes
AT longomiriam sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes
AT scappaticciolorenzo sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes
AT carusopaola sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes
AT espositokatherine sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes